– ISRAEL, Binyamina – OncoHost, a global leader in host response profiling for improved personalized cancer therapy, today announced the completion of an $8 million Series B funding round led by OurCrowd, alongside a group of family offices and private investors also participating.
OurCrowd is an investment platform built for accredited investors and institutions to invest in start-ups, early-stage companies, and venture funds.
The funding will help finance OncoHost’s ongoing clinical trials, open a US-based affiliate and prepare for the upcoming launch of PROphet, the company’s machine learning-based Host Response Profiling platform that combines proteomic analysis with AI to predict patient response to immunotherapy, providing clinicians with potential combination strategies to overcome treatment resistance.
“As the renowned entrepreneur Marc Andreesen said, ‘Software will the eat world,’ and OncoHost is proving that software will help eat cancer,” said CEO, Jon Medved. “We are excited about leading this important funding round for such a transformational company. OncoHost is demonstrating that smart software can take an already promising technology such as immunotherapy and make it so much smarter.”
“This investment round supports our mission to better predict response to immunotherapy and identify personalized treatment options for cancer patients, as we continue to expand our collaboration with pharma on clinical trials and drug development,” said Dr. Ofer Sharon, CEO of OncoHost. “Proteomic analysis is allowing us to make great advances in personalized cancer care, and we are grateful to our investors for their support in the midst of this particularly challenging time of a global pandemic. The future of personalized cancer care is no longer a distant reality but within our reach. We look forward to what 2021 holds for OncoHost.”
OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, the company aims to understand patients’ unique response to therapy and overcome one of the major obstacles in clinical oncology today – resistance to therapy. OncoHost’s Host Response Profiling platform analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to given cancer therapy. This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. PROphet also identifies potential drug targets, advancing the development of novel therapeutic strategies as well as rationally based combination therapies.
OncoHost is a clinical-stage precision oncology start-up, combining life-science research and advanced machine learning technology to develop personalized strategies for cancer patients. Clinical trials are currently focused on melanoma and non-small cell lung cancer patients and will soon expand to other indications. OncoHost’s platform, PROphet, analyzes proteomic changes in patient blood samples to detect signs of resistance to cancer therapies in real-time, enabling biomarker-guided treatment planning for physicians, target discovery for drug development, and, ultimately, improved outcomes for patients.
For more information: https://oncohost.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.